These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12043692)

  • 1. The elusive pathogenesis of von Willebrand disease Vicenza.
    Castaman G; Rodeghiero F; Mannucci PM
    Blood; 2002 Jun; 99(11):4243-4; author reply 4244. PubMed ID: 12043692
    [No Abstract]   [Full Text] [Related]  

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New families with von Willebrand disease type 2M (Vicenza).
    Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH
    Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.
    Eikenboom JC
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):365-79. PubMed ID: 11686105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic defect of type I von Willebrand disease "Vicenza" is linked to the von Willebrand factor gene.
    Randi AM; Sacchi E; Castaman GC; Rodeghiero F; Mannucci PM
    Thromb Haemost; 1993 Feb; 69(2):173-6. PubMed ID: 8456430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of variant von Willebrand's disease subtypes by analysis of functional characteristics and multimeric composition of factor VIII/von Willebrand factor.
    Ruggeri ZM; Zimmerman TS
    Ann N Y Acad Sci; 1981; 370():205-9. PubMed ID: 6791543
    [No Abstract]   [Full Text] [Related]  

  • 7. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
    Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
    Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Variants of the course of von Willebrand's disease].
    Papaian LP; Fedprova ZD; Shitikova AS; Lapis GA
    Probl Gematol Pereliv Krovi; 1981 Nov; 26(11):45-8. PubMed ID: 6798565
    [No Abstract]   [Full Text] [Related]  

  • 9. von Willebrand disease and quantitative variation in von Willebrand factor.
    Mohlke KL; Ginsburg D
    J Lab Clin Med; 1997 Sep; 130(3):252-61. PubMed ID: 9341984
    [No Abstract]   [Full Text] [Related]  

  • 10. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
    Haberichter SL; Balistreri M; Christopherson P; Morateck P; Gavazova S; Bellissimo DB; Manco-Johnson MJ; Gill JC; Montgomery RR
    Blood; 2006 Nov; 108(10):3344-51. PubMed ID: 16835381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of von Willebrand disease.
    Cox Gill J
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1277-99, viii. PubMed ID: 15511616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of bleeding severity in von Willebrand disease.
    Di Paola J
    Curr Hematol Rep; 2005 Sep; 4(5):345-9. PubMed ID: 16131434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Von Willebrand disease--a variation with an aberrant multimeric structure].
    Batlle Fonrodona J; López Fernández MF; Fernández Villamor A; López Berges C; Lasierra Cirujeda J; López Borrasca A
    Sangre (Barc); 1985; 30(2):146-53. PubMed ID: 3925572
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathophysiology of platelet-aggregating von Willebrand factor: applications of the venom coagglutinin vWF assay.
    Brinkhous KM; Read MS; Reddick RL; Griggs TR
    Ann N Y Acad Sci; 1981; 370():191-204. PubMed ID: 7023318
    [No Abstract]   [Full Text] [Related]  

  • 15. [von Willebrand factor (antigen and activity), multimer structure, and ristocetin cofactor activity].
    Goto S
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():643-6. PubMed ID: 15658412
    [No Abstract]   [Full Text] [Related]  

  • 16. ADAMTS-13 activity in von Willebrand disease.
    Perutelli P; Amato S; Molinari AC
    Thromb Res; 2006; 117(6):685-8. PubMed ID: 15993931
    [No Abstract]   [Full Text] [Related]  

  • 17. Biology of inherited coagulopathies: von Willebrand factor.
    Ginsburg D
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1011-20. PubMed ID: 1400069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.
    Mazurier C; Goudemand J; Hilbert L; Caron C; Fressinaud E; Meyer D
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):337-47. PubMed ID: 11686103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked.
    Hampshire DJ; Goodeve AC
    Haematologica; 2011 Jun; 96(6):798-800. PubMed ID: 21632843
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic approach to von Willebrand disease.
    Ng C; Motto DG; Di Paola J
    Blood; 2015 Mar; 125(13):2029-37. PubMed ID: 25712990
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.